Clinical Trial Update: Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11 [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating nivolumab plus gemcitabine for recurrent or metastatic nasopharyngeal carcinoma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Recurrent or Metastatic Nasopharyngeal Carcinom | Phase 2 | Status: COMPLETED